Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-30
2008-10-07
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S135000
Reexamination Certificate
active
07432292
ABSTRACT:
The present invention relates to novel phosphate isosteres. The invention relates to compounds having a sulfhydantoin or a reverse sulfhydantoin moiety, uses thereof, and related methods. The present invention relates to compounds of formula I or II:or pharmaceutically acceptable salts thereof; wherein Q, T, m, and X are as described herein. These compounds are inhibitors of phosphatases, particularly inhibitors of SHP-2. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing these compounds and compositions in the treatment of various phosphatase-mediated diseases.
REFERENCES:
patent: 5494925 (1996-02-01), Court et al.
patent: 5512576 (1996-04-01), Desai et al.
patent: 5541168 (1996-07-01), Court et al.
patent: 5550139 (1996-08-01), Groutas
patent: 5556909 (1996-09-01), Desai
patent: 5750546 (1998-05-01), Desai
patent: 2004/0023974 (2004-02-01), Coppola et al.
patent: WO 03/082841 (2003-10-01), None
patent: WO 2004050646 (2004-06-01), None
Mantegani, et al., “Synthesis and Antihypersensitive Activity of 2,4-Dioxoimidazolidin-1-yl and Perhydro-2,4-Dioxopyrimidin-1-yl Ergoline Derivatives”, IL Farmaco, 53 (4): 293-304 (1998).
Albericio, et al., “Synthesis of a Sulfahydantoin Library”, J. Comb. Chem. 2, 290-300 (May 2001).
Lee, et al., “Intra- and Intermolecular α—Sulfamidoalkylation Reactions”, J. Org. Chem. 55(25): 6098-6104 (1990).
Bright, et al., Journal of Immunological Methods, “Competitive particle concentration fluorescence immunoassays for measuring anti-diabetic drug levels in mouse plasma”, vol. 207 (1), pp. 23-31, (1997).
Mantegani et al., “Synthesis And Antihypertensive Activity Of 2,4-Dioxoimidazolidin-1-yl And Perhydro-2,4-Dioxopyrimidin-1-yl Ergoline Derivatives”, IL Farmaco, 53 (4): 293-304 (1998).
Bright et al, “Competitive Particle Concentration Fluorescence Immunoassays For Measuring Anti-Diabetic Drug Levels In Mouse Plasma”, Journal of Immunological Methods, 207 (1): 23-31 (1997).
Albericio et al., “Synthesis of a Sulfahydantoin Library”, J. Comb. Chem. 3, 290-300 (2001).
Kuang et al., “A General Inhibitor Scaffold for Serine Proteases with a (Chymo)trypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors”, J. Am. Chem. Soc. 121 (35): 8128-8129 (1999).
Groutas et al, Potent and Specific Inhibition of Human Leukocyte Elastase, Cathepsin G and Proteinase 3 by Sulfone Derivatives Employing the 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide Scaffold, Bioorganic & Medicinal Chemistry 6 (6): 661-671 (1998).
Groutas et al, “Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold” Biochemistry, 36(16): 4739-4750 (1997).
Dewynter et al, “Synthesis of Pseudonucleosides Containing Chiral Sulfahydantoins as Aglycone (II)”, Tetrahedron , 52 (3): 993-1004 (1996).
Muller et al., “A General Synthesis of 4-Substituted 1, 1-Dioxo-1,2,5-thiadiazolidin-3-ones Derived from alpha Amino Acids”, J. Org. Chem., 54 (18): 4471-4473 (1989).
Lee et al, “3-Oxo and 3-Imino-4-substituted-1,2,5-thiadiazolidine 1,1-Dioxides: Synthesis, Spectral Properties, and Selected Chemistry”, J. Org. Chem., 54 (13): 3077-3083 (1989).
Tremblay et al, “Efficient Solid-Phase Synthesis of Sulfahydantoins”, J. Comb. Chem., 4 (5): 429-435 (2002).
Albericio et al, “Solid Phase synthesis of Sulfahydantoins”, Tetrahedron Letters, 41 (17) 3161-3163 (2000).
Blake James F.
Miknis Gregory F.
Saunders Jeffrey O.
Anderson Rebecca L
Badia Michael C.
Barker Michael P
Vertex Pharmaceuticals Incorporated
LandOfFree
Sulfhydantoins as phosphate isosteres does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfhydantoins as phosphate isosteres, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfhydantoins as phosphate isosteres will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3995582